An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions

Bayer39,624 enrolled

Overview

This is an observational study in which data from people with cancer that has spread from the pancreas to the liver are collected and studied. These adults will include people who already received their usual treatment and who have had a certain type of imaging scan before the diagnosis of pancreatic cancer. Metastatic pancreatic cancer is a cancer that starts in the pancreas, a gland that helps to digest food, and has spread to other parts of the body. Pancreatic cancer most commonly spreads to the liver (called liver metastasis). Gadoxetate sodium-enhanced magnetic resonance imaging (EOB-MRI) is a type of imaging technique that uses a specific dye called gadoxetate sodium to produce clearer images of the liver. Participants with pancreatic cancer can be treated with surgery only if their cancer has not spread to other parts of the body. Therefore, it is important to find out if the cancer has spread to other parts of the body before performing surgery. To do this, different imaging scans such as exploratory laparoscopy and CE-CT are used. However, these tests have certain limitations, such as complicated procedures or, in some cases inaccurate results. Some studies suggest that performing EOB-MRI along with a regular CT scan may improve the chances of finding out if pancreatic cancer has spread to the liver. This imaging technique is especially helpful in detecting smaller tumors that may be missed in other types of scan. However, more information is needed to better understand the impact of EOB-MRI in Japanese people under real-world conditions. The main purpose of this study is to learn more about how using EOB-MRI helps in deciding the treatment options, how well the participants do, and how much does the use of medical care facilities costs. The main information that researchers will collect in this study: participant characteristics, including age, sex, whether they smoke or not, how well they can manage daily tasks, any other health problems they have, how advanced their cancer is, and if they have undergone laparoscopy the length of time: from the date of diagnosis of pancreatic cancer until a participant dies (called overall survival) from the date of first treatment for pancreatic cancer until the cancer spreads of other organs from the date of diagnosis of pancreatic cancer to starting the first treatment from the date of first treatment for pancreatic cancer to starting the second treatment option treatments that the participants have received, including anti-cancer drugs, radiation, and surgery the number of hospital visits, use of healthcare facilities, and related costs. The information in this study will be grouped based on the participants who had an EOB-MRI and those who had non EOB-MRI. The data will come from the participants' information stored in a database called Medical Data Vision (MDV) in Japan. Data collected will be from January 2011 to October 2022. Researchers will track individual patients' data for at least 1 year, until death, until there is no health record in the MDV for 2 months after treatment starts, or until the end of study. In this study, only available data from health records are collected. No visits or tests are required as part of this study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients having at least one confirmed diagnosis of pancreatic cancer (identified by ICD-10 diagnosis code C25.x, without a suspicious diagnosis flag) during the patient selection period * Patients having at least one active treatment record after the 1st confirmed diagnosis of pancreatic cancer * Patients 18 years of age or older at the index date * Patients having any recorded CE-CT or EOB-MRI or MRI without EOB record during the baseline period * EOB-MRI stands for enhanced liver MRI using gadoxetate sodium as the contrast agent. In this type of MRI, gadoxetate sodium is used as a contrast agent in the visualization of the liver tumor. * EOB-MRI group will include patients who underwent EOB-MRI during the baseline period. * Non-EOB-MRI group will include patients who underwent CE-CT or MRI with contrast agent other than the gadoxetate sodium during the baseline period. * MRI, CE-CT and contrast agents are identified by using the nine-digit Japanese receipt code specified in the separate code list Exclusion Criteria: * Patients with no confirmed diagnosis of pancreatic cancer (ICD-10 diagnosis code C25.x) in the below category of the disease name in the discharge summary until the 1st discharge date after the index date: * "ICD-10 code of disease name which input the most medical resources" * "ICD-10 name of disease behind hospitalization" * Patients with no active treatment within 3 months (90 days) from the con-firmed pancreatic cancer diagnosis date * Patients with no medical record in the MDV database within 1 month (30 days) from the index date

Outcomes

Primary Outcomes

Descriptive summary of patient characteristics in EOB-MRI and non-EOB-MRI group

Time frame: Up to 12 years

Descriptive summary of treatment pathways in EOB-MRI and non-EOB-MRI group

Time frame: Up to 12 years

Descriptive summary of healthcare utilization patterns in EOB-MRI and non-EOB-MRI group

Time frame: Up to 12 years

Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group

Time frame: Up to 12 years

Secondary Outcomes

Descriptive summary of patient characteristics in EOB-MRI and non-EOB-MRI group within the subgroups of interest

Subgroups: * with a record of surgery * without a record of surgery * with a record of an open-close laparotomy

Time frame: Up to 12 years

Descriptive summary of clinical outcomes in EOB-MRI and non-EOB-MRI group within the subgroups of interest

Subgroups: * with a record of surgery * without a record of surgery * with a record of an open-close laparotomy

Time frame: Up to 12 years

Descriptive summary of healthcare utilization pattern in EOB-MRI and non-EOB-MRI group within the subgroups of interest

Subgroups: * with a record of surgery * without a record of surgery * with a record of an open-close laparotomy

Time frame: Up to 12 years

Descriptive summary of healthcare costs in EOB-MRI and non-EOB-MRI group within the subgroups of interest

Subgroups: * with a record of surgery * without a record of surgery * with a record of an open-close laparotomy

Time frame: Up to 12 years

Comparison of overall survival (time from pancreatic cancer diagnosis date to death) (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)

Time frame: Up to 12 years

Comparison of time to diagnosis of new metastases from the index date (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)

Time frame: Up to 12 years

Comparison of time to first treatment pathway option from the pancreatic cancer diagnosis date (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)

Time frame: Up to 12 years

Comparison of time to second treatment pathway option from the index date (in days) between patients in the EOB-MRI and non-EOB-MRI groups within the subgroups of interest (surgery and non-surgery)

Time frame: Up to 12 years

Descriptive summary of patient characteristics across three index-year groups